ArticleCureus2025
Treatment and Follow-Up of Patients With Helicobacter pylori Infection in Primary Health Care: A Retrospective Multicenter Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction
methodsWe performed a retrospective, multicenter study on 1,478 adult patients diagnosed with HP infection through gastric biopsy, urea breath test, or stool antigen test between April 2019 and April 2024 in five primary health care units in northern Portugal. Data on demographics, antibiotic regimens, probiotic use, eradication testing, and eradication outcomes were extracted from national electronic health databases and analyzed using descriptive and inferential statistics.
resultsA total of 1,478 patients were diagnosed with HP infection (56.2% female; mean age 57.6 years), and 95.1% received treatment. Prescription patterns changed over time, with bismuth quadruple (BQ) therapy increasing from 20% to 71.3%, while clarithromycin triple (CT) therapy decreased from 44.1% to 18.5%. Probiotics were used as adjuvant therapy in only 1.3% of patients. Post-treatment eradication testing was prescribed to 69.2% of treated patients, resulting in an overall eradication rate of 84.5%. BQ therapy achieved the highest success rate at 91.8%, while CT therapy had the lowest at 72.5%.
conclusionPrimary care physicians in northern Portugal are progressively prescribing guideline-recommended BQ therapy, which demonstrated HP eradication rates above the accepted 90% benchmark. However, CT therapy remains widely used despite high antibiotic resistance and suboptimal eradication rates, and follow-up eradication testing is underutilized, underscoring important gaps in clinical practice. Updating national guidelines, reinforcing antibiotic resistance surveillance, and standardizing follow-up protocols are essential to optimize HP management in primary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.